References
- World Health Organisation. World Health Organisation, cost-effectiveness thresholds. WHO; 2012. Available at: http://www.who.int/choice/cost-effectiveness/generalized/en/ [Last accessed 1 September 2018]
- Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull WHO 2016;94:925-30
- McMurray JJV, Trueman D, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart (British Cardiac Society). 2018;104(12):1006–13]
- King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Failure 2016;4:392-402
- Patel N, Gluck J. Is Entresto good for the brain? World J Cardiol 2017;9:594-9
- Liang L, Bin-Chia Wu D, Aziz MIA, et al. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. J Med Econ 2018;21:174-81
- Kristensen SL, Martinez F, Jhund PS, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J 2016;37:3167-74
- Australian Government Department of Health. Sacubitril with valsartan, Pharmaceutical Benefits Advisory Committee Public Summary document March 2016. Available at:https://m.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-03/files/sacubitril-valsartan-psdmarch-2016.pdf [Last accessed 1 September 2018]
- Australian Government Department of Health. Sacubitril with valsartan, Pharmaceutical Benefits Advisory Committee Public Summary document July 2016. Available at: https://m.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-07/files/sacubitril-valsartan-psdjuly-2016.pdf [Last accessed 1 September 2018]
- Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 2016;1:666-72
- Sandhu AT, Ollendorf DA, Chapman RH, et al. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med 2016;165:681-9
- Jang S, Chae YK, Majhail NS. Financial conflicts of interest in economic analyses in oncology. Am J Clin Oncol 2011;34:524-8
- Valachis A, Polyzos NP, Nearchou A, et al. Financial relationships in economic analyses of targeted therapies in oncology. J Clin Oncol 2012;30:1316–20.